Improvement of social adaptation in depression with serotonin and norepinephrine reuptake inhibitors
Authors:
Open Access
- 1 September 2010
- journal article
- review article
- Published by Taylor & Francis in Neuropsychiatric Disease and Treatment
- Vol. 6 (1) , 647-655
Abstract
Depression is a disabling condition resulting in significant impairment in social functioning, involving the patient’s family, friends, work colleagues, and society at large. Although both psychologic and pharmacologic treatments generally improve many depressive symptoms, they do not always result in significant improvement in social functioning. The importance of recovery of social functioning in depressed patients is now widely appreciated, and studies are beginning to include it in evaluations of therapeutic efficacy. Among the various social adjustment evaluation rating scales, the Social Adaptation Self-Evaluation Scale, a social motivation and behavior scale, has been found to be simple to use and sensitive to change. Using this scale, the selective norepinephrine reuptake inhibitor, reboxetine, has been shown to be significantly more effective in improving social functioning than the selective serotonin reuptake inhibitor, fluoxetine. These findings are consistent with the notion that improvement in social adaptation involves functions depending primarily on noradrenergic neurotransmission. This hypothesis suggests that the serotonin and norepinephrine reuptake inhibitors, venlafaxine, duloxetine, and milnacipran, could be particularly helpful in improving social functioning. Preliminary studies with the serotonin and norepinephrine reuptake inhibitors suggest that they significantly improve social functioning. Comparative studies with selective serotonin reuptake inhibitors on the effects on social functioning should be encouraged.Keywords
This publication has 42 references indexed in Scilit:
- Milnacipran: a unique antidepressant?Neuropsychiatric Disease and Treatment, 2010
- Role of Social Support in the Relationship between Sexually Transmitted Infection and Depression among Young Women in CanadaJournal of Epidemiology, 2010
- Treatment of Seasonal Affective Disorder with Duloxetine: An Open-Label StudyPharmacopsychiatry, 2008
- Social Support and Depression among Bone Marrow Transplant PatientsJournal of Health Psychology, 2008
- Noradrenaline Might Enhance Assertive Human Social Behaviours: An Investigation in a Flatmate RelationshipPharmacopsychiatry, 2006
- The influence of social support and problematic support on optimism and depression in chronic illness: A prospective study evaluating self-esteem as a mediator.Health Psychology, 2003
- Reboxetine: its effects as measured by the Social Adaptation Self‐evaluation ScaleActa Psychiatrica Scandinavica, 2000
- Reboxetine: a double-blind comparison with fluoxetine in major depressive disorderInternational Clinical Psychopharmacology, 1999
- Do noradrenaline and serotonin differentially affect social motivation and behaviour?European Neuropsychopharmacology, 1997
- Psychosocial predictors of major affective recurrences in bipolar disorder: a 4‐year longitudinal study of patients on prophylactic treatmentActa Psychiatrica Scandinavica, 1996